Chronic Lymphocytic Leukemia New Reference: Ibrutinib and Rituximab for CLL Ulas D. Bayraktar, MD 2023-05-20
Follicular Lymphoma New Reference: SubQ Rituximab for Follicular Lymphoma Ulas D. Bayraktar, MD 2023-05-20
Waldenstrom macroglobulinemia New Reference: Bortezomib, Rituximab, Cyclophosphamide for Waldenstrom Ulas D. Bayraktar, MD 2023-03-15
Mantle cell lymphoma New Drug: Pirtobrutinib in Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2023-03-15
Chronic Lymphocytic Leukemia New Reference: Zanubrutinib for R/R CLL Ulas D. Bayraktar, MD 2023-01-10
Follicular Lymphoma New Drug: Mosunetuzumab for R/R Follicular Lymphoma Ulas D. Bayraktar, MD 2023-01-10
Diffuse Large B Cell Lymphoma New Indication: Polatuzumab in Untreated DLBCL Ulas D. Bayraktar, MD 2022-11-26
Mantle cell lymphoma New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma Ulas D. Bayraktar, MD 2022-09-20
Follicular Lymphoma New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma Ulas D. Bayraktar, MD 2022-09-20
